Detailed financial statements for CRISPR Therapeutics AG (CRSP): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Analysis Summary
CRISPR Therapeutics AG reported revenue of $3.5M in the most recent fiscal year, growing at a 5-year CAGR of 37.3%.
Trailing-twelve-month margins: gross margin -15.3%, operating margin -39.7%, net margin -33.7%.
Balance sheet quality for CRSP: current ratio of 13.3, net cash position of $1.58B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $719000 | $913.1M | $436000 | $370.0M | $35.0M | $3.5M |
| Cost of Revenue | $42.2M | $69.8M | $113.8M | $179.4M | $269.4M | $101.2M | $110.2M | $130.2M | $110.2M | $233.0M |
| Gross Profit | -$37.1M | -$28.8M | -$110.6M | $110.2M | -$268.7M | $811.9M | -$109.8M | $239.8M | -$75.2M | -$229.4M |
| Research & Development | $42.2M | $69.8M | $113.8M | $179.4M | $221.4M | $340.6M | $461.6M | $387.3M | $320.7M | $265.3M |
| Selling, General & Admin | $31.1M | $35.8M | $48.3M | $63.5M | $85.7M | $99.7M | $102.5M | $76.2M | $73.0M | $73.5M |
| Operating Expenses | $73.3M | $105.6M | $162.1M | $63.5M | $85.7M | $438.4M | $563.3M | $462.3M | $391.3M | $338.9M |
| Operating Income | -$68.1M | -$64.6M | -$158.9M | $46.7M | -$354.4M | $373.5M | -$673.2M | -$222.5M | -$466.6M | -$568.3M |
| EBITDA | -$13.7M | -$61.6M | -$155.4M | $51.5M | -$345.3M | $397.5M | -$626.3M | -$130.9M | -$343.4M | -$558.5M |
| Interest Expense | $8.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Pre-tax Income | -$22.7M | -$66.6M | -$164.4M | $67.3M | -$348.1M | $379.5M | -$650.5M | -$150.7M | -$362.7M | -$578.0M |
| Income Tax | $484000 | $1.7M | $553000 | $448000 | $809000 | $1.9M | -$325000 | $2.9M | $3.6M | $3.6M |
| Net Income | -$23.2M | -$68.4M | -$165.0M | $66.9M | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| EPS | $-1.89 | $-1.71 | $-3.44 | $1.23 | $-5.29 | $4.97 | $-8.36 | $-1.94 | $-4.34 | $-6.47 |
| EPS (Diluted) | $-1.89 | $-1.71 | $-3.44 | $1.17 | $-5.29 | $4.70 | $-8.36 | $-1.94 | $-4.34 | $-6.47 |
| Shares Outstanding (Diluted) | $12.3M | $40.1M | $48.0M | $56.9M | $65.9M | $80.4M | $77.7M | $79.2M | $84.4M | $89.9M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $315.5M | $239.8M | $456.6M | $943.8M | $1.17B | $923.0M | $211.9M | $389.5M | $298.3M | $355.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | $521.7M | $1.46B | $1.60B | $1.30B | $1.61B | $1.63B |
| Receivables | $3.2M | $2.6M | $88000 | $99000 | $10.8M | $305000 | 0 | $200.0M | $25.0M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $320.2M | $248.4M | $466.4M | $987.5M | $1.72B | $2.42B | $1.85B | $1.91B | $1.94B | $1.99B |
| Property, Plant & Equipment | $21.0M | $18.9M | $18.5M | $72.8M | $93.0M | $312.0M | $320.6M | $305.9M | $277.6M | $247.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $399000 | $344000 | $289000 | $235000 | $180000 | $125000 | $71000 | $16000 | 0 | 0 |
| Total Assets | $345.0M | $271.3M | $489.0M | $1.07B | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B | $2.27B |
| Accounts Payable | $4.6M | $1.6M | $5.1M | $5.9M | $9.1M | $14.8M | $27.4M | $38.1M | $14.7M | $11.1M |
| Short-term Debt | 0 | 0 | 0 | $8.5M | $11.4M | $12.2M | $15.8M | $15.6M | $17.3M | $18.6M |
| Total Current Liabilities | $22.0M | $14.5M | $27.7M | $57.1M | $94.3M | $119.9M | $121.1M | $108.8M | $87.8M | $149.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $188.2M |
| Total Liabilities | $112.1M | $83.5M | $96.8M | $127.3M | $163.7M | $352.4M | $367.6M | $346.8M | $310.0M | $343.4M |
| Retained Earnings | -$57.1M | -$125.4M | -$291.6M | -$224.7M | -$573.6M | -$195.9M | -$846.1M | -$999.7M | -$1.37B | -$1.95B |
| Total Equity | $232.8M | $187.8M | $392.2M | $939.4M | $1.66B | $2.40B | $1.88B | $1.88B | $1.93B | $1.92B |
| Total Debt | 0 | 0 | 0 | $52.5M | $61.4M | $225.0M | $244.0M | $238.6M | $223.7M | $394.9M |
| Net Debt | -$315.5M | -$239.8M | -$456.6M | -$891.2M | -$1.63B | -$2.15B | -$1.57B | -$1.46B | -$1.68B | -$1.58B |
| Working Capital | $298.2M | $233.9M | $438.6M | $930.4M | $1.62B | $2.30B | $1.73B | $1.80B | $1.85B | $1.84B |
Cash Flow (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$23.2M | -$68.4M | -$165.0M | $66.9M | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| Depreciation & Amortization | $925000 | $3.0M | $3.5M | $4.7M | $9.2M | $18.0M | $24.2M | $19.8M | $19.3M | $19.5M |
| Stock-based Compensation | $10.8M | $18.9M | $35.0M | $44.1M | $66.0M | $102.4M | $97.9M | $81.0M | $86.6M | $72.5M |
| Change in Working Capital | $1.8M | -$25.4M | $10.6M | -$48.4M | $33.4M | $26.9M | $19.8M | -$193.6M | $156.3M | $71.9M |
| Operating Cash Flow | -$55.3M | -$70.1M | -$96.2M | $56.7M | -$238.4M | $539.0M | -$495.7M | -$260.4M | -$142.8M | -$345.0M |
| Capital Expenditure | -$3.0M | -$7.8M | -$2.8M | -$6.7M | -$18.4M | -$81.7M | -$37.2M | -$9.5M | -$1.9M | -$914000 |
| Acquisitions | -$100000 | 0 | 0 | 0 | $522.8M | $953.7M | $221.5M | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | -$57000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$58.3M | -$77.9M | -$99.0M | $50.0M | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +693.9% | -92.4% | +9169.8% | -99.8% | +126893.2% | -100.0% | +84762.4% | -90.5% | -90.0% | |
| Net Income Growth (YoY) | -194.6% | -141.4% | +140.5% | -621.8% | +208.3% | -272.2% | +76.4% | -138.4% | -58.8% | |
| EPS Growth (YoY) | +9.5% | -101.2% | +135.8% | -530.1% | +194.0% | -268.2% | +76.8% | -123.7% | -49.1% | |
| Shares Change (YoY) | +226.8% | +19.7% | +18.7% | +15.8% | +21.9% | -3.3% | +1.9% | +6.5% | +6.6% | |
| FCF Growth (YoY) | -33.6% | -27.1% | +150.5% | -613.5% | +278.1% | -216.5% | +49.4% | +46.4% | -139.1% | |
| Gross Margin | -717.9% | -70.3% | -3541.9% | 38.1% | -37369.7% | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| Operating Margin | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| EBITDA Margin | -264.7% | -150.3% | -4975.2% | 17.8% | -48018.2% | 43.5% | -143653.2% | -35.4% | -981.2% | -15911.3% |
| Net Margin | -449.3% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| FCF Margin | -1129.5% | -190.0% | -3169.4% | 17.3% | -35705.7% | 50.1% | -122231.4% | -72.9% | -413.4% | -9855.5% |
| Effective Tax Rate | -2.1% | -2.6% | -0.3% | 0.7% | -0.2% | 0.5% | 0.0% | -1.9% | -1.0% | -0.6% |
Per-Share Data (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-4.76 | $-1.94 | $-2.06 | $0.88 | $-3.89 | $5.69 | $-6.85 | $-3.41 | $-1.71 | $-3.85 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $12.3M | $40.0M | $48.0M | $54.4M | $65.9M | $75.9M | $77.7M | $79.2M | $84.4M | $89.9M |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Gross Margin | -1534.39% |
| Operating Margin | -3971.53% |
| Net Margin | -3368.72% |
Financial Health
| Debt / Equity | 0.45 |
| Current Ratio | 17.85 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -10.72 | -13.73 | -8.31 | 49.52 | -28.94 | 15.25 | -4.86 | -32.27 | -9.07 | -8.11 |
| P/B | 1.07 | 5.00 | 3.49 | 3.53 | 6.07 | 2.40 | 1.69 | 2.63 | 1.72 | 2.45 |
| P/S | 48.09 | 22.89 | 438.61 | 11.44 | 14043.89 | 6.30 | 7248.62 | 13.40 | 94.87 | 1343.50 |
| Gross Margin | -717.9% | -70.3% | -3541.9% | 38.1% | -37369.7% | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| Operating Margin | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Net Margin | -449.3% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
Related companies: ACLX · AKRO · ARWR · CYTK · KRYS · MTSR · NUVL
Explore sector: Healthcare · Biotechnology
More sections of CRSP: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks